Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control (Q37351709)
Jump to navigation
Jump to search
scientific article published on 05 September 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control |
scientific article published on 05 September 2013 |
Statements
1 reference
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control (English)
1 reference
Martin Ridderstråle
1 reference
Robbyna Svaerd
1 reference
Cordula Zeller
1 reference
Gabriel Kim
1 reference
Hans J Woerle
1 reference
Uli C Broedl
1 reference
EMPA-REG H2H-SU trial investigators
1 reference
1 reference
Identifiers
1 reference